Marketing-authorisation holder
Braeburn
1 medicine in 1 country, as authorisation holder.
Medicines
Every medicine in the registers under its name, current ones first.
1 medicine
| Medicine | Substance | Country | Status | Authorised |
|---|---|---|---|---|
| BRIXADI128mg/0.36ml (356mg/ml) | 16mg/0.32ml (50mg/ml) | 24mg/0.48ml (50mg/ml) | 32mg/0.64ml (50mg/ml) | 64mg/0.18ml (356mg/ml) | 8mg/0.16ml (50mg/ml) | 96mg/0.27ml (356mg/ml) · Solution, extended release | Buprenorphine | United States | Marketed | 2023 |
Countries
Where it holds or makes medicines, with how many are current.
| Country | Medicines | Current | Past | Companies |
|---|---|---|---|---|
| United States | 1 | 1 | 0 | CompaniesAll medicines |
Top substances
The active substances in most of its medicines.
Sources and licences
At a glance
- Type
- Marketing-authorisation holder
- Medicines
- 1
- Countries
- 1
- Roles
- Authorisation holder
Work with Prognia
Keep Braeburn’s medicines accurate on Prognia, see how professionals use them and answer what they ask. A 20-minute call, in English.
Book a call